1 January 2024 v2025.59.1 limited_company_frs_102_section_1a_v1_1_2 companies_houseSoftwarefalsetruetruetrueNo description of principal activityfalsexbrli:purexbrli:sharesiso4217:GBP143890282024-01-012024-12-31143890282024-12-3114389028bus:Director12024-01-012024-12-3114389028bus:RegisteredOffice2024-01-012024-12-31143890282022-09-302023-12-31143890282023-12-3114389028core:WithinOneYear2024-12-3114389028core:WithinOneYear2023-12-3114389028core:ShareCapital2024-12-3114389028core:ShareCapital2023-12-3114389028core:RetainedEarningsAccumulatedLosses2024-12-3114389028core:RetainedEarningsAccumulatedLosses2023-12-3114389028core:RetainedEarningsAccumulatedLosses2022-09-302023-12-3114389028core:ShareCapital2022-09-302023-12-3114389028core:ShareCapital2024-01-0114389028core:RetainedEarningsAccumulatedLosses2024-01-01143890282024-01-0114389028core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3114389028core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-01-012024-12-3114389028core:OfficeEquipment2024-01-012024-12-3114389028core:IntangibleAssetsOtherThanGoodwill2024-01-0114389028core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3114389028core:IntangibleAssetsOtherThanGoodwill2024-12-3114389028core:IntangibleAssetsOtherThanGoodwill2023-12-3114389028core:PlantMachinery2024-12-3114389028core:PlantMachinery2024-01-0114389028core:PlantMachinery2024-01-012024-12-3114389028core:PlantMachinery2023-12-311438902812024-01-012024-12-3114389028countries:EnglandWales2024-01-012024-12-3114389028bus:AuditExempt-NoAccountantsReport2024-01-012024-12-3114389028bus:PrivateLimitedCompanyLtd2024-01-012024-12-3114389028bus:SmallEntities2024-01-012024-12-3114389028bus:FullAccounts2024-01-012024-12-31
Company registration number:
14389028
Omnia Therapy Limited
Unaudited Financial Statements for the year ended
31 December 2024
Omnia Therapy Limited
Officers and Professional Advisers
Year ended
31 December 2024
Director
H Mehmet-Quirk
Registered office
2nd Floor 10 Charles Ii Street
London
SW1Y 4AA
England
Omnia Therapy Limited
Director's Report
Year ended
31 December 2024
The director presents the report and the unaudited
financial statements
of the company for the year ended 31 December 2024.

Change of company name

Directors

The director who served the company during the year was as follows:
H Mehmet-Quirk

Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
This report was approved by the board of directors on
15 September 2025
and signed on behalf of the board by:
H Mehmet-Quirk
Director
Omnia Therapy Limited
Report to the board of directors on the preparation of the unaudited statutory financial statements of Omnia Therapy Limited
Year ended
31 December 2024
As described on the statement of financial position, the Board of Directors of
Omnia Therapy Limited
are responsible for the preparation of the
financial statements
for the year ended
31 December 2024
, which comprise the income statement, statement of financial position, statement of changes in equity and related notes.
You consider that the company is exempt from an audit under the Companies Act 2006.
In accordance with your instructions I have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and from information and explanations supplied to me.
Animo Associates Limited
De Burgh House, Second floor
Market Road
Wickford
Essex
SS12 0FD
United Kingdom
Omnia Therapy Limited
Income Statement
Year ended
31 December 2024
Year to 31 Dec 2024Period from 30 Sep 2022 to 31 Dec 2023
££
Turnover
9,052
 
5,945
 
Cost of sales
(94,948
 ) (66,600 )
Gross loss
(85,896
 )
(60,655
 )
Administrative expenses
(48,942
 )
(23,229
 )
Other operating income -  
317
 
Operating loss
(134,838
 )
(83,567
 )
Other interest receivable and similar income
8
 
1
 
Loss before tax
(134,830
 )
(83,566
 )
Tax on loss -   -  
Loss for the financial year
(134,830
 )
(83,566
 )
The company has no other recognised items of income or expense other than the results for the year as set out above.
Omnia Therapy Limited
Statement of Financial Position
31 December 2024
20242023
Note££
Fixed assets    
Intangible assets 5
33,441
 
16,577
 
Tangible assets 6
662
 
1,104
 
34,103
 
17,681
 
Current assets    
Debtors 7
6,036
  -  
Cash at bank and in hand
650
 
1,235
 
6,686
 
1,235
 
Creditors: amounts falling due within one year 8
(259,085
 )
(102,382
 )
Net current liabilities
(252,399
 )
(101,147
 )
Total assets less current liabilities (218,296 ) (83,466 )
Capital and reserves    
Called up share capital
100
 
100
 
Profit and loss account
(218,396
 )
(83,566
 )
Shareholders deficit
(218,296
 )
(83,466
 )
For the year ending
31 December 2024
, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
  • The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
  • The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These
financial statements
have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
These
financial statements
were approved by the board of directors and authorised for issue on
15 September 2025
, and are signed on behalf of the board by:
H Mehmet-Quirk
Director
Company registration number:
14389028
Omnia Therapy Limited
Statement of Changes in Equity
Year ended
31 December 2024
Called up share capitalProfit and loss accountTotal
£££
At 30 September 2022 -   -   -  
Loss for the period- (83,566)(83,566)
Total comprehensive income for the period- 
(83,566
)
(83,566
)
Issue of shares
100
 - 
100
 
Total investments by and distributions to owners
100
 - 
100
 
At 31 December 2023 and 
1 January 2024
100
 
(83,566
)
(83,466
)
Loss for the year- (134,830)(134,830)
Total comprehensive income for the year- 
(134,830
)
(134,830
)
At
31 December 2024
100
 
(218,396
)
(218,296
)
Omnia Therapy Limited
Notes to the Financial Statements
Year ended
31 December 2024

1 General information

The company is a private company limited by shares and is registered in England and Wales. The address of the registered office is
2nd Floor 10 Charles Ii Street
,
London
,
SW1Y 4AA
, England.

2 Statement of compliance

These
financial statements
have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable to the UK and Republic of Ireland'.

3 Accounting policies

Basis of preparation

The
financial statements
have been prepared on the historical cost basis, as modified by the revaluation of certain assets.
The
financial statements
are prepared in sterling, which is the functional currency of the company.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Intangible assets

Intangible assets are initially measured at cost and are subsequently measured at cost less any accumulated amortisation and accumulated impairment losses or at a revalued amount. However, Intangible assets acquired as part of a business combination are only recognised separately from goodwill when they arise from contractual or other legal rights, are separable, the expected future economic benefits are probable and the cost or value can be measured reliably.
Any intangible assets carried at a revalued amount are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses.
An increase in the carrying amount of an asset as a result of a revaluation is recognised in other comprehensive income and accumulated in capital and reserves. However, the increase is recognised in profit or loss to the extent that it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves. If a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess is recognised in profit or loss.
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:
Development costs
33% straight line

Tangible assets

Tangible assets are initially measured at cost, and are subsequently measured at cost less any accumulated depreciation and accumulated impairment losses or at a revalued amount.
Any tangible assets carried at a revalued amount are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
An increase in the carrying amount of an asset as a result of a revaluation is recognised in other comprehensive income and accumulated in capital and reserves. However, the increase is recognised in profit or loss to the extent that it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves. If a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess is recognised in profit or loss.
Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:
Office equipment
33% straight line

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.
Basic financial instruments are initially recognised at the transaction price and are subsequently measured as follows: Debt instruments are subsequently measured at amortised cost and commitments to receive a loan and to make a loan to another entity are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.
All other financial instruments, including derivatives, are initially recognised at fair value, which is normally the transaction price and are subsequently measured at fair value, with any changes recognised in profit or loss.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.
All equity instruments regardless of significance, and other financial assets that are individually significant, are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics.
Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Defined contribution pension plan

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

4 Average number of employees

The average number of persons employed by the company during the year was
1
(2023:
1.00
).

5 Intangible assets

Other intangible assets
£
Cost  
At
1 January 2024
24,865
 
Additions
25,506
 
At
31 December 2024
50,371
 
Amortisation  
At
1 January 2024
8,288
 
Charge
8,642
 
At
31 December 2024
16,930
 
Carrying amount  
At
31 December 2024
33,441
 
At 31 December 2023
16,577
 

6 Tangible assets

Plant and machinery etc.
£
Cost  
At
1 January 2024
and
31 December 2024
1,325
 
Depreciation  
At
1 January 2024
221
 
Charge
442
 
At
31 December 2024
663
 
Carrying amount  
At
31 December 2024
662
 
At 31 December 2023
1,104
 

7 Debtors

20242023
££
Other debtors
6,036
  -  

8 Creditors: amounts falling due within one year

20242023
££
Trade creditors
66,722
 
7,060
 
Amounts owed to group undertakings and undertakings in which the company has a participating interest
159,775
 
82,174
 
Taxation and social security
32,588
 
12,746
 
Other creditors -  
402
 
259,085
 
102,382